Presence of coronary plaques in patients with nonalcoholic fatty liver disease

Radiology

Volumn 254, Issue 2, 2010, Pages 393-400

  Assy, Nimer ^a   Djibre, Agness ^a   Farah, Raymond ^a   Grosovski, Maria ^b   Marmor, Alon ^a,c  

^a ZIV MEDICAL CENTER   (Israel)

^b ORT BRAUDE COLLEGE   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IOMEPROL; IOPAMIDOL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; STENOSIS; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; FATTY LIVER; METHODOLOGY; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDY; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FATTY LIVER; FEMALE; HUMANS; IOPAMIDOL; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77449127455     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09090769     Document Type: Article

References (41)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-1231.
2. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45(10):1929-1934.
3. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8(3):521-533, viii.
4. Perseghin G, Lattuada G, De Cobelli F, et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab 2006;91(12):5122-5125.
5. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005;11(37):5834-5839.
6. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124(1):71-79.
7. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980;137(3):727-729.
8. Akahoshi M, Amasaki Y, Soda M, et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001;24(4):337-343.
9. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50(8):1844-1850.
10. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortal ity from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110(10):1245-1250.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III). JAMA 2001;285(19):2486-2497.
12. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13(10):1579-1584.
13. Motoyama S, Kondo T, Anno H, et al. Atherosclerotic plaque characterization by 0.5-mm-slice multislice computed tomo graphic imaging. Circ J 2007;71(3):363-366.
14. Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography(MSCT). Circ J 2008;72(4):618-625.
15. Jinzaki M, Sato K, Tanami Y, et al. Novel method of displaying coronary CT angiography: angiographic view. Circ J 2006;70(12):1661-1662.
16. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model: The Mexico City Diabetes Study. Diabetes Care 1996;19(10):1138-1141.
17. Montagne P, Laroche P, Cuillière ML, Varcin P, Pau B, Duheille J. Microparticle-enhanced nephelometric immunoassay for human C-reactive protein. J Clin Lab Anal 1992;6(1):24-29.
18. Clauss A. Rapid physiological coagulation method in determination of fibrinogen [in German]. Acta Haematol 1957;17(4):237-246.
19. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19(1):100-106.
20. Baker H, Frank O, De Angelis B, Feingold S. Plasma alpha-tocopherol in man at various time intervals after ingesting free or acetylated tocopherol. Nutr Rep Int 1980;21:531-536.
21. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids 1987;45(2-4):337-351.
22. Schroeder S, Kopp AF, Baumbach A, et al. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol 2001;37(5):1430-1435.
23. Zhang S, Levin DC, Halpern EJ, Fischman D, Savage M, Walinsky P. Accuracy of MDCT in assessing the degree of stenosis caused by calcified coronary artery plaques. AJR Am J Roentgenol 2008;191(6):1676-1683.
24. Hong C, Becker CR, Schoepf UJ, Ohnesorge B, Bruening R, Reiser MF. Coronary artery calcium: absolute quantification in non-enhanced and contrast-enhanced multi-detector row CT studies. Radiology 2002;223(2):474-480.
25. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137(1):1-10.
26. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365(9468): 1415-1428.
27. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865-873.
28. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J Biol Chem 2004;279(31):32345-32353.
29. Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29(6):1325-1330.
30. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42(2):473-480.
31. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-2207.
32. Kawachi S, Takeda N, Sasaki A, et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25(3):617-621.
33. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990;10(4):493-496.
34. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118(4):1388-1393.
35. Licata G, Argano C, Di Chiara T, Parrinello G, Scaglione R. Obesity: a main factor of metabolic syndrome? Panminerva Med 2006;48(2):77-85.
36. Pundziute G, Schuijf JD, Jukema JW, et al. Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol 2007;49(1):62-70.
37. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992;69(8):729-732.
38. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS): CASS participating investigators and staff. J Am Coll Cardiol 1993;22(4):1141-1154.
39. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-239.
40. Smith SC Jr, Allen J, Blair SN, et al. AHA/ ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update - endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113(19):2363-2372.
41. Mitsutake R, Niimura H, Miura S, et al. Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J 2006; 70(9):1122-1127.